AbbVie, Genmab Bi-Specific Lymphoma Data Tee Up Potential Challenge to Roche Drug

AbbVie and Genmab have reported data on their recently approved bi-specific antibody in a second cancer indication, positioning them to talk to regulators about filings to challenge Roche.